We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+1.29%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$8.89B
AUM Growth
-$1.49B
(-14%)
Cap. Flow
-$1.55B
Cap. Flow
% of AUM
-17.42%
Top 10 Holdings %
Top 10 Hldgs %
47.67%
Holding
1,012
New
106
Increased
478
Reduced
302
Closed
124
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Energy Transfer Partners
ET
|
+$37.3M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$31.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$27.8M |
| 4 |
Newmont
NEM
|
+$27.4M |
| 5 |
Cummins
CMI
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$430M |
| 2 |
JPMorgan Chase
JPM
|
+$168M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$132M |
| 4 |
Yum! Brands
YUM
|
+$105M |
| 5 |
Pfizer
PFE
|
+$92.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 59.33% |
| 2 | Technology | 6.01% |
| 3 | Healthcare | 4.63% |
| 4 | Consumer Discretionary | 3.72% |
| 5 | Financials | 3.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Humana
HUM
$46.7B
| $1.36M | 0.02% |
2,941
-288
| -9% | -$127K |
|
327
LXP Industrial Trust
LXP
$3.53B
| $1.33M | 0.02% |
17,018
-1,959
| -10% | -$145K |
|
|
CPRX
328
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.32M | 0.01% |
194,494
-5,906
| -3% | -$38.8K |
|
329
Syndax Pharmaceuticals
SNDX
$1.84B
| $1.27M | 0.01% |
58,179
-1,414
| -2% | -$26.1K |
|
330
MannKind Corp
MNKD
$1.28B
| $1.27M | 0.01% |
+290,784
| New | +$1.35M |
|
|
RAPT
331
DELISTED
RAPT Therapeutics
RAPT
| $1.26M | 0.01% |
4,274
-243
| -5% | -$65K |
|
332
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.1B
| $1.22M | 0.01% |
23,822
-75
| -0.3% | -$3.9K |
|
|
EFC
333
Ellington Financial
EFC
$1.68B
| $1.22M | 0.01% |
+71,495
| New | +$1.27M |
|
334
National Health Investors
NHI
$3.9B
| $1.22M | 0.01% |
21,252
-75
| -0.4% | -$4.15K |
|
|
RC
335
Ready Capital
RC
$265M
| $1.21M | 0.01% |
+77,450
| New | +$1.21M |
|
|
DAWN
336
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.21M | 0.01% |
+71,668
| New | +$1.47M |
|
337
Arcutis Biotherapeutics
ARQT
$3.42B
| $1.21M | 0.01% |
58,203
-3,375
| -5% | -$67.2K |
|
338
Omega Healthcare
OHI
$15.4B
| $1.2M | 0.01% |
40,531
+23,850
| +143% | +$696K |
|
339
Sabra Healthcare REIT
SBRA
$5.64B
| $1.18M | 0.01% |
87,243
+6,972
| +9% | +$98.7K |
|
340
Artisan Partners
APAM
$2.79B
| $1.17M | 0.01% |
24,552
-239
| -1% | -$11.5K |
|
|
PMT
341
PennyMac Mortgage Investment
PMT
$849M
| $1.16M | 0.01% |
+67,057
| New | +$1.27M |
|
342
Annaly Capital Management
NLY
$16.9B
| $1.16M | 0.01% |
+36,932
| New | +$1.24M |
|
343
SiriusXM
SIRI
$10B
| $1.15M | 0.01% |
18,149
-2,058
| -10% | -$129K |
|
344
MacroGenics
MGNX
$235M
| $1.14M | 0.01% |
70,889
-4,008
| -5% | -$75.4K |
|
345
Immunovant
IMVT
$8.09B
| $1.13M | 0.01% |
133,092
-7,860
| -6% | -$64.9K |
|
346
Arcturus Therapeutics
ARCT
$157M
| $1.13M | 0.01% |
30,505
-1,754
| -5% | -$71.5K |
|
347
Estee Lauder
EL
$29B
| $1.11M | 0.01% |
3,012
-192
| -6% | -$65.2K |
|
348
uniQure
QURE
$2.68B
| $1.11M | 0.01% |
+53,470
| New | +$1.53M |
|
349
AnaptysBio
ANAB
$1.6B
| $1.11M | 0.01% |
31,831
-1,792
| -5% | -$56.8K |
|
|
CMPS
350
Compass Pathways
CMPS
$1.52B
| $1.07M | 0.01% |
+48,290
| New | +$1.54M |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, ALPS Advisors held 1,012 positions worth $8.89B, down 14% from $10.4B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
ALPS Advisors withdrew a net $1.55B in Q4 2021, closing 124 positions and reducing 302 holdings. Its most notable exit was Berkshire Hathaway Class A, an estimated $430M position sold in full.
By sector, the portfolio is most concentrated in Energy at 59% of assets, up from 51% a quarter earlier, followed by Technology and Healthcare.
Against the trend, ALPS Advisors opened a new position in Bristol-Myers Squibb worth $29.6M.
- ALPS Advisors's largest Q4 2021 buy was Bristol-Myers Squibb: 474,459 shares worth $29.6M.
- ALPS Advisors added most to Energy Transfer Partners in Q4 2021, an estimated $37.3M increase.
- ALPS Advisors's biggest Q4 2021 reduction was JPMorgan Chase, cutting an estimated $168M.
- ALPS Advisors fully exited Berkshire Hathaway Class A in Q4 2021, selling an estimated $430M.
- ALPS Advisors's ten largest holdings make up 48% of its $8.89B portfolio in Q4 2021.
- ALPS Advisors opened 106 new positions and closed 124 in Q4 2021.
- ALPS Advisors's portfolio value fell 14% quarter-over-quarter to $8.89B.
Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.